Anti-glomerular basement membrane disease

Kidney International

Volumn 64, Issue 4, 2003, Pages 1535-1550

  Pusey, Charles D ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Autoimmune glomerulonephritis; Crescentic glomerulonephritis; Goodpasture's syndrome; Nephrotoxic nephritis; Plasma exchange

Indexed keywords

BRONCHODILATING AGENT; CYCLOPHOSPHAMIDE; PREDNISOLONE;

ADULT; ANAMNESIS; ANTI GLOMERULAR BASEMENT MEMBRANE DISEASE; ASTHMA; BLOOD EXAMINATION; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULOPATHY; HEMATURIA; HUMAN; KIDNEY BIOPSY; LABORATORY TEST; MALE; NEUTROPENIA; OXYGEN SATURATION; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; REVIEW; URINALYSIS; WESTERN BLOTTING;

EID: 0141786763     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00241.x     Document Type: Review

References (94)

1. WILSON CB, DIXON FJ: Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 3:74-89, 1973
2. KLUTH DC, REES AJ: Anti-glomerular basement membrane disease. J Am Soc Nephrol 10:2446-2453, 1999
3. SALAMA AD, LEVY JB, LIGHTSTONE L, PUSEY CD: Goodpasture's disease. Lancet 358:917-920, 2001
4. BOLTON WK: Nephrology Forum: Goodpasture's syndrome. Kidney Int 50:1753-1766, 1996
5. STANTON MC, TANGE JD: Goodpasture's syndrome. Aust N Z J Med 7:132-144, 1958
6. GOODPASTURE E: The significance of certain pulmonary lesions in relation to the etiology of influenza. Am J Med Sci 158:863-870, 1919
7. SCHEER R, GROSSMAN MA: Immune aspects of the glomerulonephritis associated with pulmonary haemorrhage. Ann Intern Med 60:1009-1021, 1964
8. DUNCAN D, DRUMMOND KN, MICHAEL AF, VERNIER RL: Pulmonary haemorrhage and glomerulonephritis. Report of six cases and study of the renal lesion by the fluorescent antibody technique and electron microscopy. Ann Intern Med 62:920-938, 1965
9. LEVY JB, TURNER AN, REES AJ, PUSEY CD: Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 134:1033-1042, 2001
10. DONAGHY M, REES AJ: Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet 2:1390-1393, 1983
11. JAYNE DR, MARSHALL PD, JONES SJ, LOCKWOOD CM: Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int 37:965-970, 1990
12. SALAMA AD, DOUGAN T, LEVY JB, et al: Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. Am J Kidney Dis 39:1162-1167, 2002
13. REES AJ, PETERS DK, COMPSTON DA, BATCHELOR JR: Strong association between HLA-DRW2 and antibody-mediated Goodpasture's syndrome. Lancet 1:966-968, 1978
14. FISHER M, PUSEY CD, VAUGHAN RW, REES AJ: Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes. Kidney Int 51:222-229, 1997
15. PHELPS RG, REES AJ: The HLA complex in Goodpasture's disease: A model for analyzing susceptibility to autoimmunity. Kidney Int 56:1638-1653, 1999
16. PHELPS RG, JONES V, TURNER AN, REES AJ: Properties of HLA class II molecules divergently associated with Goodpasture's disease. Int Immunol 12:1135-1143, 2000
17. KASHTAN CE, MICHAEL AF: Alport syndrome. Kidney Int 50:1445-1463, 1996
18. KALLURI R, TORRE A, SHIELD CF, III, et al: Identification of alpha3, alpha4, and alpha5 chains of type IV collagen as alloantigens for Alport posttransplant anti-glomerular basement membrane antibodies. Transplantation 69:679-683, 2000
19. SMEETS HJ, KNOERS VV, VAN DE HEUVEL LP, et al: Hereditary disorders of the glomerular basement membrane. Pediatr Nephrol 10:779-788, 1996
20. STEVENSON A, YAQOOB M, MASON H, et al: Biochemical markers of basement membrane disturbances and occupational exposure to hydrocarbons and mixed solvents. Q J Med 88:23-28, 1995
21. LEVY JB, LACHMANN RH, PUSEY CD: Recurrent Goodpasture's disease. Am J Kidney Dis 27:573-578, 1996
22. KALLURI R, DANOFF TM, OKADA H, NEILSON EG: Susceptibility to anti-glomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice. J Clin Invest 100:2263-2275, 1997
23. NAKAMURA A, YUASA T, UJIKE A, et al: Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: A novel murine model for autoimmune glomerular basement membrane disease. J Exp Med 191:899-906, 2000
24. MEYERS KE, ALLEN J, GEHRET J, et al: Human antiglomerular basement membrane autoantibody disease in XenoMouse II. Kidney Int 61:1666-1673, 2002
25. SADO Y, NAITO I, AKITA M, OKIGAKI T: Strain specific responses of inbred rats on the severity of experimental autoimmune glomerulonephritis. J Clin Lab Immunol 19:193-199, 1986
26. REYNOLDS J, MAVROMATIDIS K, CASHMAN SJ, et al: Experimental autoimmune glomerulonephritis (EAG) induced by homologous and heterologous glomerular basement membrane in two substrains of Wistar-Kyoto rat. Nephrol Dial Transplant 13:44-52, 1998
27. SADO Y, BOUTAUD A, KAGAWA M, et al: Induction of anti-GBM nephritis in rats by recombinant alpha 3(IV)NC1 and alpha 4(IV)NC1 of type IV collagen. Kidney Int 53:664-671, 1998
28. RYAN JJ, REYNOLDS J, NORGAN VA, PUSEY CD: Expression and characterization of recombinant rat alpha 3(IV)NC1 and its use in induction of experimental autoimmune glomerulonephritis. Nephrol Dial Transplant 16:253-261, 2001
29. SADO Y, NAITO I, OKIGAKI T: Transfer of anti-glomerular basement membrane antibody-induced glomerulonephritis in inbred rats with isologous antibodies from the urine of nephritic rats. J Pathol 158:325-332, 1989
30. WU J, HICKS J, OU C, et al: Glomerulonephritis induced by recombinant collagen IV alpha 3 chain noncollagen domain 1 is not associated with glomerular basement membrane antibody: A potential T cell-mediated mechanism. J Immunol 167:2388-2395, 2001
31. WU J, HICKS J, BORILLO J, et al: CD4(+) T cells specific to a glomerular basement membrane antigen mediate glomerulonephritis. J Clin Invest 109:517-524, 2002
32. REYNOLDS J, PUSEY CD: In vivo treatment with a monoclonal antibody to T helper cells in experimental autoimmune glomerulonephritis in the BN rat. Clin Exp Immunol 95:122-127, 1994
33. NISHIKAWA K, LINSLEY PS, COLLINS AB, et al: Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur J Immunol 24:1249-1254, 1994
34. REYNOLDS J, TAM FW, CHANDRAKER A, et al: CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J Clin Invest 105:643-651, 2000
35. REYNOLDS J, NORGAN VA, BHAMBRA U, et al: Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis. J Am Soc Nephrol 13:359-369, 2002
36. REYNOLDS J, PUSEY CD: Oral administration of glomerular basement membrane prevents the development of experimental autoimmune glomerulonephritis in the WKY rat. J Am Soc Nephrol 12:61-70, 2001
37. LOCKWOOD CM, THIRU S, STEWART S, et al: Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. Q J Med 89:903-912, 1996
38. HAGEN EC, DE KEIZER RJ, ANDRASSY K, et al: Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Clin Nephrol 43:351-359, 1995
39. TIPPING PG, KITCHING AR, CUNNINGHAM MA, HOLDSWORTH SR: Immunopathogenesis of crescentic glomerulonephritis. Curr Opin Nephrol Hypertens 8:281-286, 1999
40. KITCHING AR, HOLDSWORTH SR, TIPPING PG: IFN-gamma mediates crescent formation and cell-mediated immune injury in murine glomerulonephritis. J Am Soc Nephrol 10:752-759, 1999
41. KITCHING AR, TIPPING PG, HOLDSWORTH SR: IL-12 directs severe renal injury, crescent formation and Th1 responses in murine glomerulonephritis. Eur J Immunol 29:1-10, 1999
42. TIPPING PG, KITCHING AR, HUANG XR, et al: Immune modulation with interleukin-4 and interleukin-10 prevents crescent formation and glomerular injury in experimental glomerulonephritis. Eur J Immunol 27:530-537, 1997
43. HOLDSWORTH SR, KITCHING AR, TIPPING PG: Chemokines as therapeutic targets in renal disease. Curr Opin Nephrol Hypertens 9:505-511, 2000
44. TOPHAM PS, CSIZMADIA V, SOLER D, et al: Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J Clin Invest 104:1549-1557, 1999
45. LLOYD CM, MINTO AW, DORF ME, et al: RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 185:1371-1380, 1997
46. LI S, HOLDSWORTH SR, TIPPING PG: Antibody independent crescentic glomerulonephritis in mu chain deficient mice. Kidney Int 51:672-678, 1997
47. LI S, KURTS C, KONTGEN F, et al: Major histocompatibility complex class II expression by intrinsic renal cells is required for crescentic glomerulonephritis. J Exp Med 188:597-602, 1998
48. WAKAYAMA H, HASEGAWA Y, KAWABE T, et al: Abolition of antiglomerular basement membrane antibody-mediated glomerulonephritis in FcRgamma-deficient mice. Eur J Immunol 30:1182-1190, 2000
49. SUZUKI Y, SHIRATO I, OKUMURA K, et al: Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. Kidney Int 54:1166-1174, 1998
50. SHEERIN NS, SPRINGALL T, CARROLL MC, et al: Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice. Clin Exp Immunol 110:403-409, 1997
51. SOGABE H, NANGAKU M, ISHIBASHI Y, et al: Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J Immunol 167:2791-2797, 2001
52. ROBSON MG, COOK HT, BOTTO M, et al: Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice. J Immunol 166:6820-6828, 2001
53. YANAGITA M, ISHIMOTO Y, ARAI H, et al: Essential role of Gas6 for glomerular injury in nephrotoxic nephritis. J Clin Invest 110:239-246, 2002
54. TAM FW, SMITH J, MOREL D, et al: Development of scarring and renal failure in a rat model of crescentic glomerulonephritis. Nephrol Dial Transplant 14:1658-1666, 1999
55. ERWIG LP, KLUTH DC, REES AJ: Macrophages in renal inflammation. Curr Opin Nephrol Hypertens 10:341-347, 2001
56. KARKAR AM, SMITH J, PUSEY CD: Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha. Nephrol Dial Transplant 16:518-524, 2001
57. YANG N, NIKOLIC-PATERSON DJ, NG YY, et al: Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): Potential role of MIF in regulating glucocorticoid production. Mol Med 4:413-424, 1998
58. COOK HT, SINGH SJ, WEMBRIDGE DE, et al: Interleukin-4 ameliorates crescentic glomerulonephritis in Wistar Kyoto rats. Kidney Int 55:1319-1326, 1999
59. LAI PC, COOK HT, SMITH J, et al: Interleukin-11 attenuates nephrotoxic nephritis in Wistar Kyoto rats. J Am Soc Nephrol 12:2310-2320, 2001
60. KLUTH DC, AINSLIE CV, PEARCE WP, et al: Macrophages transfected with adenovirus to express IL-4 reduce inflammation in experimental glomerulonephritis. J Immunol 166:4728-4736, 2001
61. TANG WW, QI M, WARREN JS: Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti-GBM Ab GN. Kidney Int 50:665-671, 1996
62. FENG L, CHEN S, GARCIA GE, et al: Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 [Rapid Communication]. Kidney Int 56:612-620, 1999
63. KAWASAKI K, YAOITA E, YAMAMOTO T, et al: Antibodies against intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 prevent glomerular injury in rat experimental crescentic glomerulonephritis. J Immunol 150:1074-1083, 1993
64. ALLEN AR, MCHALE J, SMITH J, et al: Endothelial expression of VCAM-1 in experimental crescentic nephritis and effect of antibodies to very late antigen-4 or VCAM-1 on glomerular injury. J Immunol 162:5519-5527, 1999
65. TOMITA N, MORISHITA R, LAN HY, et al: In vivo administration of a nuclear transcription factor-kappaB decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephrol 11:1244-1252, 2000
66. COOK HT, KHAN SB, ALLEN A, et al: Treatment with an antibody to VLA-1 integrin reduces glomerular and tubulointerstitial scarring in a rat model of crescentic glomerulonephritis. Am J Pathol 161:1265-1272, 2002
67. LOCKWOOD CM, ELLIOTT JD, BREITMAN L, et al: Anti-adhesion molecule therapy as an interventional strategy for autoimmune inflammation. Clin Immunol 93:93-106, 1999
68. SAVAGE CO, PUSEY CD, BOWMAN C, et al: Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res) 292:301-304, 1986
69. LERNER RA, GLASSOCK RJ, DIXON FJ: The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med 126:989-1004, 1967
70. SAUS J, WIESLANDER J, LANGEVELD JP, et al: Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem 263:13374-13380, 1988
71. TURNER N, MASON PJ, BROWN R, et al: Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen. J Clin Invest 89:592-601, 1992
72. SALAMA AD, PUSEY CD: Immunology of anti-glomerular basement membrane disease. Curr Opin Nephrol Hypertens 11:279-286, 2002
73. CASHMAN SJ, PUSEY CD, EVANS DJ: Extraglomerular distribution of immunoreactive Goodpasture antigen. J Pathol 155:61-70, 1988
74. PUSEY CD, DASH A, KERSHAW MJ, et al: A single autoantigen in Goodpasture's syndrome identified by a monoclonal antibody to human glomerular basement membrane. Lab Invest 56:23-31, 1987
75. RYAN JJ, MASON PJ, PUSEY CD, TURNER N: Recombinant alpha-chains of type IV collagen demonstrate that the amino terminal of the Goodpasture autoantigen is crucial for antibody recognition. Clin Exp Immunol 113:17-27, 1998
76. HELLMARK T, SEGELMARK M, UNGER C, et al: Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease. Kidney Int 55:936-944, 1999
77. NETZER KO, LEINONEN A, BOUTAUD A, et al: The Goodpasture autoantigen. Mapping the major conformational epitope(s) of alpha3(IV) collagen to residues 17-31 and 127-141 of the NC1 domain. J Biol Chem 274:11267-11274, 1999
78. BORZA DB, NETZER KO, LEINONEN A, et al: The Goodpasture autoantigen. Identification of multiple cryptic epitopes on the NC1 domain of the alpha3(IV) collagen chain. J Biol Chem 275:6030-6037, 2000
79. DAVID M, BORZA DB, LEINONEN A, et al: Hydrophobic amino acid residues are critical for the immunodominant epitope of the Goodpasture autoantigen. A molecular basis for the cryptic nature of the epitope. J Biol Chem 276:6370-6377, 2001
80. BORZA DB, BONDAR O, TOOD P, et al: Quaternary organization of the Goodpasture autoantigen, the alpha 3(IV) collagen chain. Sequestration of two cryptic autoepitopes by intrapromoter interactions with the alpha4 and alpha5 NC1 domains. J Biol Chem 277:40075-40083, 2002
81. NOLASCO FE, CAMERON JS, HARTLEY B, et al: Intraglomerular T cells and monocytes in nephritis: study with monoclonal antibodies. Kidney Int 31:1160-1166, 1987
82. DERRY CJ, ROSS CN, LOMBARDI G, et al: Analysis of T cell responses to the autoantigen in Goodpasture's disease. Clin Exp Immunol 100:262-268, 1995
83. SALAMA AD, CHAUDHRY AN, RYAN JJ, et al: In Goodpasture's disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3(IV)NC1. J Am Soc Nephrol 12:1908-1915, 2001
84. LOCKWOOD C, REES AJ, PEARSON TA, et al: Immunosuppression and plasma exchange in the treatment of Goodpasture's syndrome. Lancet 1:711-715, 1976
85. JOHNSON JP, MOORE J, JR, AUSTIN HA, III, et al: Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 64:219-227, 1985
86. WALKER RG, SCHEINKESTEL C, BECKER GJ, et al: Clinical and morphological aspects of the management of crescentic anti-glomerular basement membrane antibody (anti-GBM) nephritis/Goodpasture's syndrome. Q J Med 54:75-89, 1985
87. BOUGET J, LE POGAMP P, PERRIER G, et al: Anti-basement-membrane antibody mediated, rapidly progressive, glomerulonephritis. Diagnostic and therapeutic strategy based on a retrospective study of 14 cases. Ann Med Interne (Paris) 141:409-415, 1990
88. HERODY M, BOBRIE G, GOUARIN C, et al: Anti-GBM disease: Predictive value of clinical, histological and serological data. Clin Nephrol 40:249-255, 1993
89. MERKEL F, PULLIG O, MARX M, et al: Course and prognosis of antibasement membrane antibody (anti-BM-Ab)-mediated disease: Report of 35 cases. Nephrol Dial Transplant 9:372-376, 1994
90. DALY C, CONLON PJ, MEDWAR W, WALSHE JJ: Characteristics and outcome of anti-glomerular basement membrane disease: A single-center experience. Ren Fail 18:105-112, 1996
91. JAYNE D, RASMUSSEN N, ANDRASSY K, et al: Randomized trial of cyclophosphamide versus azathioprine as remission maintenance therapy for ANCA-associated vasculitis (CYCAZAREM). N Engl J Med 349:36-44, 2003
92. BYGREN P, FREIBURGHAUS C, LINDHOLM T, et al: Goodpasture's syndrome treated with staphylococcal protein A immunoadsorption. Lancet 2:1295-1296, 1985
93. REYNOLDS J, COOK PR, RYAN JJ, et al: Segregation of experimental autoimmune glomerulonephritis as a complex genetic trait and exclusion of Col4a3 as a candidate gene. Exp Nephrol 10:402-407, 2002
94. SAVAGE C: Nephrology Forum: ANCA-associated renal vasculitis. Kidney Int 60:1614-1627, 2001